A case of patient with renal lupus with an initial presentation of hemolytic uremic syndrome triggered by streptococcal infection

Rahaf Z. Attar, Enas I. Ramel, Osama Y. Safdar & Sherif Desoky

1College of medicine, King Abdulaziz University, Jeddah, Saudi Arabia
2Faculty of Medicine, Pediatric Nephrology Center of Excellence, King Abdulaziz University, Jeddah, Saudi Arabia

Correspondence
Osama Y. Safder, King Abdulaziz University, PO Box 80215, Jeddah 21589, Saudi Arabia.
Tel: 009665605620849; Fax: 00966(2)
6655728; E-mail: safderosama@hotmail.com

Funding Information
No sources of funding were declared for this study.

Received: 22 July 2016; Revised: 30 August 2017; Accepted: 5 January 2018

Clinical Case Reports 2018; 6(4): 712–718
doi: 10.1002/ccr3.1425

Introduction
Systemic lupus erythematosus (SLE) is a systemic autoimmune illness that can affect any organ or part of the body. The disease usually presents at an early age and has a median age of onset of 12–13 years. SLE is significantly more prevalent in females than in males, with a female-to-male ratio of 11:1 [1]. According to some studies, certain manifestations are more commonly found in early-onset SLE, including malar rash, renal involvement, and hematological abnormalities such as hemolytic anemia and thrombocytopenia [2]. The disease is diagnosed upon fulfillment of a certain number of clinical and laboratory criteria.

Renal involvement is common in patients with SLE. Indeed, several different patterns of renal disease are observed in patients with SLE, with immune complex-mediated glomerular disease being the most common. Other patterns that present less frequently include tubulointerstitial and vascular diseases (e.g., thrombotic microangiopathy) [3, 4].

Hemolytic uremic syndrome (HUS) is a type of thrombotic microangiopathy defined by the presence of the classical triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. The majority of cases are caused by the Shiga-like toxin produced by Escherichia coli, and the presence of this toxin makes dysentery (bloody diarrhea) a common associated feature. This form of the disease is classified as typical HUS. Comparatively, the other type of HUS, which represents only a minority of cases, is not caused by the organism and moreover is not associated with bloody diarrhea. In fact, this type is linked to certain genetic abnormalities and complement dysregulation; hence, this type is called atypical HUS (aHUS) [5].

The literature contains very few reported cases of patients with SLE who first presented with HUS, and nearly all cases are associated with the atypical form. The several hypotheses regarding why such associations occur will be discussed later in this study.

In this report, we describe the case of a 9-year-old boy who presented with a history of pharyngitis and non-bloody diarrhea for a few weeks prior to admission; he was admitted to the hospital due to symptoms related to severe anemia and jaundice. The results of a laboratory work-up and histopathological examination were
consistent with thrombotic microangiopathy and stage IV lupus nephritis. Thus, a diagnosis of HUS secondary to SLE was established.

Case Report

Focused history

We report the case of a 9-year-old Saudi male who presented at King Abdulaziz University Hospital with a 3-day history of pallor, lethargy, shortness of breath, and headache. Along with these manifestations, the family noticed a yellowish discoloration of the sclera. The patient was in optimal health, with no significant medical complaints, until 2 weeks prior to hospital admission, a time when he developed symptoms of upper respiratory tract infection (i.e., a sore throat, cough, and mild subjective fever). One week later, he developed diarrhea with a frequency greater than 5 times daily. The diarrhea was yellowish in color and without blood. Furthermore, the diarrhea was associated with epigastric pain and vomiting, and it resolved a few days later; however, the epigastric pain became more severe, and his vomiting continued. Due to this situation, the patient had been unable to maintain his usual appetite and had lost some weight. The patient also reported a decrease in the amount of his urine and a change of the urine’s color, which was described by the mother as tea-colored. No rash or edema was reported.

The patient was referred to our tertiary hospital by a dispensary after their results revealed red and granular casts in the urine and abnormal kidney function.

Focused physical examination

An initial assessment revealed that the patient had a rapid but regular heart rate of 118 beats/min. His respiratory rate was 20/min, his blood pressure was 119/61 mmHg, and his oxygen saturation was 100%.

Examination showed that the patient was conscious and oriented; he was pale and had yellowish sclera but exhibited no other significant signs (i.e., no periorbital or lower limb edema, skin rash, or petechia). His chest was clear, and the heart sounds were normal, with no additional sounds or murmurs. A neurological examination was unremarkable.

Based on the initial assessment and the laboratory work-up, (Table 1) hemolytic uremic syndrome was strongly suspected due to the presence of the classical triad of the disease. The diagnosis of PSGN was unlikely for several reasons, although the patient had a high ASO titer; this only confirmed a previous exposure and not an infection. Additionally, another more probable disease, i.e., HUS, better explained the abnormal kidney function and urine analysis. Unfortunately, we were unable to obtain a throat swab results and get an evidence of a streptococcal infection. Thus, PSGN could not be completely ruled out.

Surprisingly, the patient also exhibited a positive immune profile for SLE (i.e., ANA and dsDNA). So far, a clear diagnosis of the acute kidney injury was difficult to be made. For this reason, a kidney biopsy was indicated.

Histopathology

Light microscopy

Light microscopic examination of 33 glomeruli revealed two distinctive patterns. A glomerular disease pattern was observed that involved diffuse thickening and a double contour of the glomerular basement membrane with severe mesangial expansions, segmental endocapillary proliferation of 13 glomeruli, and a few other glomeruli with membranoproliferative patterns. Additionally, a few glomeruli exhibited cellular crescent formations. Marked glomerular congestion with intracapillary leukocyte infiltration was present in nearly half of the glomeruli, and moderate edema of the interstitium with mild mixed inflammation and no fibrosis was also present (Fig. 1–3).

A microangiopathic occlusive pattern was noted. Some of the glomeruli exhibited global ischemic collapse with marked glomerular congestion. Several hilar arterioles exhibited fibrinoid necrosis occluding the lumina with intraluminal fibrin thrombi and concentric fibrointimal hyperplasia (Fig. 4–6).

Immunofluorescence study

We observed +3 coarse granular positivity along with the capillary loop and mesangium for C3 and IgG and +2 for IgM (Fig. 5), with trace positivity for C1q and negative staining for C4.

Final diagnosis

The diffuse proliferative sclerosing pattern that was observed along with early crescent formation and the positive results for ANA and anti-dsDNA antibodies confirmed the diagnosis of stage IV lupus nephritis according to Systemic Lupus Collaborating Clinics (SLICC) criteria. [6]

Additionally, the microangiopathic picture, which included the presence of fibrin thrombi occluding the lumina and global ischemic collapse, confirmed HUS. The patient likely had an atypical form of the disease because no organisms or blood were detected in his stool.
presence of SLE supports this diagnosis because SLE is known to be a secondary cause of aHUS.

**Hospital course**

Initially, the patient received supportive treatment for his kidney injury and packed RBCs for his severe anemia. Following local guidelines, the patient was given six IV doses of methylprednisolone pulses, i.e., 600 mg/m² per dose, due to our initial suspicion of rapidly progressive glomerulonephritis and eventually to minimize his organ damage and control his SLE flare.

During his hospital stay, the patient started to develop edema and hypertension. He required dialysis three times, and an additional three blood transfusions. Plasma exchange was not available at our hospital at that time. Fortunately, the patient had improved on the supportive management given and did not need plasma exchange or transfusion.

Eventually, he was discharged home after his kidney function was normalized with both 1 mg/kg of prednisone and monthly injections of 1 mg/m² of cyclophosphamide for 5 months.

**Follow-up**

No follow-up information or repeated tests were obtained as the patient’s family decided to continue his management in a different hospital.

**Discussion**

SLE is an autoimmune multisystemic disease that has a myriad of clinical presentations. One or two organs are usually initially involved, and other organs might be involved after a certain period of time. A French multicenter study [7] that included 155 pediatric patients with SLE demonstrated that the most commonly involved systems
in the initial presentation of SLE are the hematological and musculoskeletal systems, with percentages of 72% and 64%, respectively. Renal involvement is less common and occurs in only 50% of the pediatric population compared with 23% of adults [8]. Half of all patients with SLE with kidney disease have a clinically evident disease that presents with symptoms of acute kidney injury, chronic renal failure, nephrotic and nephritic syndromes; the other half presents with subclinical diseases such as an asymptomatic elevation in creatinine, abnormal urine analysis, or kidney pathology [9]. The present case is interesting because of the unusual and distinctive presentation of lupus nephritis a thrombotic microangiopathy.

There are few similar cases reported in the literature involving patients with SLE who initially present with HUS [10–15]. (Table 2)

All of these cases were associated with aHUS. There are several hypotheses regarding why such an association would occur. Antiphospholipid antibodies, complement dysregulation, and infections have been suggested to play roles in the pathogenesis of thrombotic microangiopathy in patients with SLE.

The literature includes several reported SLE cases with renal thrombotic microangiopathy significantly associated with the presence of antiphospholipid antibodies [10, 16, 17]. For example, Bridoux et al. [16]. evaluated eight patients with SLE with renal thrombotic microangiopathy, and antiphospholipid antibodies were found in five of these patients. This finding reveals the significant association between antiphospholipid antibodies and the thrombotic microangiopathic complications of SLE. However, the presence of HUS/thrombotic thrombocytopenic purpura (TTP) was only established in one patient. This hypothesis is not relevant to our case because our patient had unremarkable antiphospholipid antibody levels. Nonetheless, further assessment of this association is needed.

Genetic defects and complement dysregulation are important suggested etiologies of aHUS. In fact, it has been estimated that at least 50% of patients with aHUS have genetic mutations for the following complement proteins: Factor H, I, and B, and CD46 [18, 19]. Factor H (i.e., a complement regulator of the alternative complement pathway) in particular was found to be correlated with both SLE and aHUS. Recent studies have demonstrated that people with factor H deficiencies are susceptible to SLE.

Figure 3. Segmental double contour of the glomerular basement membrane.

Figure 4. Segmental fibrinoid necrosis.

Figure 5. Hilar arteriole exhibiting intimal fibrinoid necrosis occluding the lumen.
Moreover, such deficiency accelerates the development of lupus nephritis [20]. Other studies have also implicated low factor H levels in the pathogenesis of aHUS, causing thrombotic microangiopathy due to endothelial injury and platelet consumption [21].

Infection is another factor that has been correlated with the occurrence of thrombotic microangiopathy in patients with SLE. Ming-Han Chen et al. [22], evaluated 25 patients with SLE who developed thrombotic microangiopathy either after or simultaneous with the diagnosis of SLE, revealing association with infections in 16 of the 25 patients (64%).

Because our patient complained of pharyngitis and presented with prodromal diarrhea before his hospital admission, we believe that an infection might have been the trigger in this case. However, we do not have any valid evidence of an infection to support our claim.

Conditions other than HUS have been associated with thrombotic microangiopathy in SLE, including TTP, catastrophic antiphospholipid syndrome, malignant hypertension, and scleroderma [23].

The presentations of HUS and TTP are very similar [24]. If the occlusive thrombotic pattern is associated with the classical clinical triad (i.e., renal failure, thrombocytopenia, and microangiopathic hemolytic anemia), the diagnosis of HUS is more likely, as previously discussed. In contrast, TTP usually manifests with a pentad that includes the same symptoms as HUS in addition to neurological deficit and fever, both of which were absent in our patient. However, half of patients with TTP lack one or more of these classical symptoms, which makes it difficult to clinically distinguish between the diseases, particularly when the suspected HUS is atypical and no organism or toxin can be identified. Several studies have established that vWF-cleaving protease activity is typically low in TTP cases due to a defect in the ADAMTS13 gene, whereas this level is normal in HUS. This single parameter can be used to distinguish between the diseases when needed [25].

In general, renal thrombotic microangiopathy when associated with SLE indicates a serious complication that increases morbidity and mortality.

Plasmapheresis is one measure that has been demonstrated to remarkably increase the remission rate and decrease the mortality of these patients as well as any patient with aHUS in general. The established mortality rate for plasma exchange-treated patients is 25%, and that for untreated patients is 57% [26, 27].

Table 1. Laboratory findings.

| Test         | Results                                |
|--------------|----------------------------------------|
| CBC          | Hb 4.8 g/dL (N: 12–14 g/dL), MCV 80.6 fL (N: 78–98 fL), platelet 128 × 10⁹/L (N: 150–400 × 10⁹/L), WBC: 13.9 × 10⁹/L (N: 4–11 × 10⁹/L), RBC 1.8 (N: 4.2–5.4 × 10¹² M/μL), reticulocyte 11.61% (N: 5–1.5) |
| Blood film   | Schistocyte +2, bite cells (+)         |
| U&E          | Urea 50.7 mmol/L (N: 2.5–6.4 mmol/L), creatinine 632 mmol/L (N: 53–115 μmol/L) |
| Urine        | Hb +3, protein +2                      |
| Urine analysis | albumin/creatinine ratio 2222.290 mg/g (N: 0–30 mg/g), protein ++ mg/dL |
| Immune profile | Antistreptolysin-O (ASO) antibody 533 IU/mL (N: 0–200 IU/mL), C3 0.45 g/L (N: 0.75–1.65 g/L), anti-C4 antibody 0.15 (N: 0.2–0.6 g/L), antinuclear antibody (ANA) 1:320 moderate positive, anti-double-stranded DNA (dsDNA) 247.6 IU/mL (N: 0–200 IU/mL), anticardiolipin antibody-M: 1.6 U/mL (N: 0–7 U/mL), anti-B2-glycoprotein IgG: 0.08 U/mL (N: 0–10 U/mL) |
| Coombs test  | Negative                               |
| Throat swab  | Unavailable results due to improper specimen |
| Stool analysis | Negative for verotoxin-producing organisms, and no RBCs were detected. |
| Other tests  | LDH: 1610 IU/L (N: 105–333 IU/L), haptoglobin < 0.3 g/L (N: 0.5–3.2 g/L), CRP: 8 mg/L (N: 0–3 mg/L), serum albumin 27 g/L (N: 40.2–47.6 g/L) |

CBC, complete blood count; CRP, C-Reactive protein; Hb, hemoglobin; LDH, lactate dehydrogenase; MCV, mean cell volume; RBC, red blood cells; WBC, white blood cells.

Figure 6. (a, b) Small artery exhibiting intimal fibrinoid necrosis and concentric fibrointimal hyperplasia occluding the lumen, with intimal leukocytes in the wall.
Response to plasma exchange in patients with aHUS depends on the type of complement deficiency. Two-thirds of patients with complement H and I deficiencies experience remission from the disease. Other types are more likely to recur [28]. Nonetheless, all reported cases in which HUS was implicated as an initial presentation of SLE improved following treatment with prednisolone and an immunosuppressive agent with or without plasmapheresis or infusion. This indicates that the outcome of aHUS in SLE is generally favorable.

Eculizumab, a monoclonal antibody against C5 is a newer treatment option for patients with aHUS. It has the same efficacy in patients with and without known mutations. Studies to date have demonstrated that eculizumab normalizes renal function in aHUS patients and decreases the frequency of renal dialysis. It is even effective in patients who are refractory to plasma exchange and patients who have undergone renal transplantation [29, 30].

Our patient was also treated with prednisone and cyclophosphamide, but no plasmapheresis or plasma infusion was required. Most children with hemolytic uremic syndrome recover after conservative management. Moreover, plasma exchange is generally reserved for more severe and atypical cases.

### Conclusion

There are several reported cases in the literature of patients with SLE who first present with thrombotic microangiopathy. Antiphospholipid antibodies, infections, and complement dysregulation have been suggested to play roles in these cases. Despite all of these associations, the underlying pathophysiology remains unknown, and further studies are required. The outcomes of aHUS in patients with SLE are generally favorable.

## Conflict of Interest

None declared.

## Authorship

RA: First author, reviewed literature wrote the abstract & discussion. OS: corresponding Co-author, reviewed the manuscript. ER: co-author, wrote the clinical presentation and references. SD: Senior co-author, reviewed the manuscript.

## References

1. Danchenko, N., J. Satia, and M. Anthony. 2006. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15:308–318.
2. Livingston, B., A. Bonner, and J. Pope. 2011. Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus 20:1345–1355.
3. Descombes, E., D. Droz, L. Drouet, J. Grünfeld, and P. Lesavre. 1997. Renal vascular lesions in lupus nephritis. Medicine 76:355–368.
4. Park, M., V. D’Agati, G. Appel, and C. Pirani. 2008. Tubulointerstitial disease in lupus nephritis: relationship to
immune deposits, interstitial inflammation, glomerular changes, renal function, and prognosis. Nephron 44: 309–319.
5. Robson, W., A. Leung, and B. Kaplan. 1993. Hemolytic-uremic syndrome. Current Problems. Pediatrics 23:16–33.
6. Petri, M., A. M. Orbai, G. S. Alarcón, C. Gordon, J. T. Merrill, P. R. Fortin, et al. 2012. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 64:2677–2686.
7. Bader-Meunier, B., J. Armengaud, E. Haddad, R. Salomon, G. Deschênes, I. Koné-Paut, et al. 2005. Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study. J. Pediatr. 146:648–653.
8. Sasidharan, P., M. Bindya, and K. Sajeeth Kumar. 2012. Hematological Manifestations of SLE at initial presentation: is it underestimated? ISRN Hematol. 2012:1–5.
9. Wallace, D. J., and B. H. Hahn, eds. 2007. Pp. 1112–1130. Dubois’ Lupus Erythematosus. 7th ed.. Lippincott Williams & Wilkins, Philadelphia, PA.
10. Morioka, S., H. Makino, J. Wada, K. Shikata, Y. Yamasaki, T. Ogura, et al. 1995. A case of systemic lupus erythematosus associated with severe fibrinoid necrosis located mainly in the glomerular afferent arteriole. Nihon Jinzo Gakkai Shi. 37:69–73.
11. Ogawa, T., H. Arai, K. Maruyama, T. Watanabe, Y. Kobayashi, O. Kikuchi, et al. 2000. Association of systemic lupus erythematosus and hemolytic uremic syndrome in a child. Pediatr. Nephrol. 14:62–64.
12. Tsao, C., S. Hsueh, and J. Huang. 2001. Initial presentation of hemolytic uremic syndrome in a boy with systemic lupus erythematosus. Rheumatol. Int. 21:161–164.
13. Kawasaki, Y., J. Suzuki, R. Nozawa, S. Suzuki, and H. Suzuki. 2002. A 12-year-old girl with hemolytic uremic syndrome as initial symptom of systemic lupus erythematosus and a literature review. Am. J. Nephrol. 22:576–580.
14. Rabbani, M. A., B. Ahmad, S. F. Mekan, S. Muzzafar, and S. S. Ali. 2005. Systemic lupus erythematosus presenting as hemolytic uremic syndrome: a case report. J. Pak. Med. Assoc. 55:84–87.
15. Azharuddin, M., and M. A. Bhatti. 2003. Hemolytic uremic syndrome with systemic lupus erythematosus. J. Coll. Physicians Surg. Pak. 15:306–308.
16. Bridoux, F., F. Vrtovský, C. Noël, P. Saunier, B. Mougenot, V. Lemaître, et al. 1998. Renal thrombotic microangiopathy in systemic lupus erythematosus: clinical correlations and long-term renal survival. Nephrol. Dial. Transplant. 13:296–302.
17. Espinosa, G., S. Buccarelli, R. Cervera, M. Lozano, J. C. Reverter, G. de la Red, et al. 2004. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann. Rheum. Dis. 63: 730–736.
18. Noris, M., and G. Remuzzi . 2005. Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management? Nat. ClinPractNephrol. 1:2.
19. Geerdink, L. M., D. Westra, J. A. van Wijk, E. M. Dormreijen, M. R. Lilien, J. C. Davin, et al. 2012. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr. Nephrol. 27:1283.
20. Bao, L., M. Haas, and R. J. Quigg. 2011. Complement factor H deficiency accelerates development of lupus nephritis. J. Am. Soc. Nephrol. 22:285–295.
21. Kim, J., M. McCulloch, S. Marks, A. Waters, and D. Noone. 2015. The clinical spectrum of hemolytic uremic syndrome secondary to complement factor H autoantibodies. Clin. Nephrol. 83:49–56.
22. Chen, M.-H., W.-S. Chen, P. Mu-Hsin Chang, H. T. Lee, H. Y. Lin, and D. F. Huang. 2011. Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan. Rheumatology (Oxford) 50:768–775.
23. Song, D., L. Wu, F. Wang, X. Yang, D. Zhu, M. Chen, et al. 2013. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res. Ther. 15:R12.
24. Barbour, T., S. Johnson, S. Cohnley, and P. Hughes. 2012. Thrombotic microangiopathy and associated renal disorders. Nephrol. Dial. Transplant. 27:2673–2685.
25. Remuzzi, G. 2002. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 100:778–785.
26. Li, Q.-Y., F. Yu, F.-D. Zhou, and M.-H. Zhao. 2016. Plasmapheresis is associated with better renal outcomes in lupus nephritis patients with thrombotic microangiopathy: a case series study. Medicine (Baltimore) 95:e3595.
27. Nesher, G., V. Hanna, T. Moore, M. Hersh, and T. Osborn. 1994. Thrombotic microangiopathic hemolytic anemia in systemic lupus erythematosus. Semin. Arthritis Rheum. 24:165–172.
28. Caprioli, J., M. Noris, S. Brioschi, G. Pianetti, F. Castelletti, P. Bettinghio, et al. 2006. Genetics of HUS :the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108:1267.
29. Tschumi, S., M. Gugger, B. S. Bucher, M. Riedl , and G. D. Simonetti . 2011. Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings. Pediatr. Nephrol. 26:2085–2088.
30. Weitz, M., O. Amon, D. Bassler, A. Koenigsrainer, and S. Nadalin. 2011. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr. Nephrol. 26:1325–1329.